Founder Metrics in Longevity Startups

When we founded LongeVC in 2021, we knew well enough that longevity biotech is a whole different ball game than other industries. The founders we backed weren't building consumer apps where new user acquisition could validate product-market fit in a matter of weeks. They were developing epigenetic age reversal therapies, senolytic compounds, or AI drug discovery platforms—often developed toward age-related diseases recognized by regulators.

From the beginning, we had a clear framework for assessing longevity-focused founders. This framework goes beyond the typical VC checklist of team match and market size. It focuses on what actually matters: scientific credibility, strategic patience, translational thinking, and the ability to design teams for an Ironman Triathlon, not a sprint.

In software or consumer tech, investors track monthly recurring revenue, user acquisition cost, and growth rates. But in longevity biotech, none of these may apply at the early stages. A company developing partial cellular reprogramming therapies might not see revenue for years. A diagnostics startup creating a liquid biopsy for age-related diseases might spend 18 months just validating its assay.

This creates what we call the longevity paradox: the companies with the highest potential impact often show no clear signs of conventional success. The risk profile is fundamentally different as well. While software startups can pivot quickly when something doesn't work, traditional longevity and biotech companies face binary outcomes at regulatory checkpoints. A failed Phase II trial doesn't just mean iterating on the product—it can mean years of additional work, millions in new capital, and potentially starting over with a different patient population or indication. These aren't agile pivots; they're expensive, time-consuming strategic shifts that require new clinical trials, regulatory resubmissions, and patient recruitment. We need founders who understand this reality and have structured their companies to derisk at every stage.

So what should investors evaluate instead? After four years and hundreds, if not thousands, of portfolio conversations, we've identified five critical founder traits that actually predict success in longevity biotech.

The first thing we evaluate is the uniqueness of proposed solutions. Is the idea groundbreaking or offers a different approach to what other teams are already working on? And this is crucial as it determines the risks as well as rewards of such investments. From there, we go on to evaluate scientific credibility. This isn't just about researchers having a PhD from an Ivy League institution, though that certainly helps in many cases. We're looking for depth of expertise in the specific biological mechanisms their company is targeting. Can the founder explain the underlying science with precision and clarity? Have they published peer-reviewed research in their domain? Do they have collaborations with leading academic labs?

Take Anastasia Georgievskaya of Haut.AI, one of our portfolio companies. Before founding Haut.AI, she worked with Alex Zhavoronkov at Insilico Medicine, where she contributed to research on AI applications for skin analysis. She co-authored, alongside Konstantin Kiselev, the influential PhotoAgeClock paper, developing non-invasive visual biomarkers of aging, and later published a single-author study in Plastic and Reconstructive Surgery on AI-based performance evaluation methods. Her work evidenced that she was at the forefront of advancing the science itself.

Scientific credibility also means understanding what you don't know. The best founders in longevity surround themselves with world-class scientific advisors who can challenge their hypotheses and strengthen their research approach. Whether they're working on gene therapies for age-related diseases, regenerative approaches for specific conditions, or diagnostic tools, founders need deep domain expertise and the humility to recognize when they need additional scientific guidance.

We've seen too many startups built on shaky foundations—founders who cherry-pick data or make claims that don't withstand scrutiny. In longevity, where the bar for evidence is high and the regulatory pathway is complex, weak science is a fatal flaw.

Scientific brilliance means little if it can't translate into clinical results. The founders we back demonstrate translational thinking—the ability to see a clear path from their research to patient benefit. This requires an understanding not just of biology, but also of regulations, clinical trial design, reimbursement landscapes, and commercial strategy.

When we evaluate a founder's translational thinking, we ask: Have they identified a clear therapeutic focus? Do they understand which indication to pursue first, even if their technology has multiple applications? Have they mapped out the regulatory pathway and identified potential bottlenecks? Most importantly, have they considered how their innovation will benefit the greatest number of people possible?

Regulations around longevity call for a careful strategy. Because the FDA does not recognize aging as a disease, our portfolio companies focus on specific age-related diseases and conditions such as cancer, neurodegenerative diseases, cardiovascular issues, and metabolic disorders. They use the same FDA pathways as other biotech companies: biologics for therapies and established device pathways for diagnostics. Rather than focusing on “treating aging,” we back founders who leverage biology—from diagnostics to therapies—to help people live better and longer within existing, proven regulatory frameworks.

One of the most critical traits we evaluate is what we call strategic patience. Longevity biotech isn't a field for founders seeking quick exits. The companies we invest in are addressing fundamental aging mechanisms and underlying conditions, which necessitate a sustained commitment over many years. We need founders who understand that the time frames of such therapies from discovery to approval are extended; they can even take a decade or more. And this also entails being strategic with financial decisions and leveraging partnerships and non-dilutive capital to de-risk at the right time.

This doesn't mean moving slowly. Strategic patience is about sustainable velocity—moving fast on the science while maintaining stamina for the long journey ahead. It means having a realistic understanding of regulatory timelines, capital requirements, and the iterative nature of the drug development process. Founders who project overly optimistic timelines often burn out their teams and lose investor confidence when reality sets in.

Evaluating strategic patience means assessing whether founders have built financial models that account for extended timelines and multiple funding rounds. It means understanding whether they've preserved enough equity to stay motivated through a decade of development. Founder dilution across multiple rounds can become problematic if not managed carefully from the start.

Getting team composition right is one of the most critical factors in a longevity startup's success. And that is a blend of scientific, regulatory, and business expertise to navigate each development stage.

The most common gap we see is the absence of business acumen. Many longevity founders come from strong academic and research backgrounds but lack experience managing investors or commercializing inventions. This challenge is especially acute in longevity, where the science is cutting-edge but the business models are slightly behind.

The much-sought-after founders recognize early that scientific brilliance alone isn't enough—they need to understand business or actively seek that expertise. Strong founders demonstrate business acumen in several ways: they understand the standard biotech business models (partnerships, licensing, M&A, IPO), they think strategically about capital efficiency and runway, they can articulate clear value inflection points to investors, and they know when to bring in business professionals to complement their scientific leadership. We look for founders who are self-aware about their gaps and proactive about filling them, whether that means hiring a seasoned COO, building a strong board with commercial experience, or spending time learning the business side of biotech.

From day one, we advise portfolio companies to add business development expertise. R&D-only teams cannot scale. Successful longevity companies strike a balance between scientific leadership and operational excellence, hiring experts in clinical development, regulatory affairs, and strategic partnerships. This doesn't mean the founding scientist needs to step aside. It means surrounding them with the right team to execute on their vision.

We also look for diverse perspectives on founding teams. Longevity is inherently interdisciplinary, combining biology, chemistry, clinical medicine, and data science. Teams that bring together different disciplines often see connections that others miss and can pivot more effectively when faced with challenges.

Longevity is capital-intensive, but the best founders find ways to be strategic about resource allocation. They prioritize experiments that derisk the most critical hypotheses and leverage academic collaborations and government grants before raising dilutive capital. They design studies that generate multiple data points, not just yes/no answers.

Capital efficiency doesn't mean being cheap but being smart. It's the difference between spending $5M to validate a mechanism in mice before raising a large Series A, versus burning through $15M trying to do everything at once. The founders who think this way preserve optionality and maintain investor confidence through inevitable setbacks.

We also evaluate milestone discipline: the ability to break a decade-long vision into achievable 12-18 month increments. Each milestone should derisk a key assumption—target engagement, pharmacokinetics, safety in a relevant model. Founders who can articulate clear milestones and consistently hit them prove their ability to execute in this demanding environment.

Unlike traditional startups, in some early-stage longevity companies, success can’t be measured in revenue or user growth. In which case, instead, we track biological milestones: preclinical validation in animal models, successful IND submissions, Phase I safety data, proof of mechanism in humans, and strategic partnerships with larger pharmaceutical companies.

These milestones serve as proxies for progress toward the ultimate goal: therapies that extend human healthspan and lifespan. Each milestone reduces risk, validates the science, and brings therapeutic companies closer to clinical impact. Although not all longevity startups follow this path, diagnostics companies and AI platforms like Haut.AI measure success differently. For them, key milestones include commercial partnerships with major brands, regulatory clearances for diagnostic tools, or achieving technical benchmarks like accuracy thresholds. The common thread is systematic derisking: proving the technology works, demonstrating market demand, and building a sustainable business model.

We also evaluate whether founders are building companies that can withstand the test of time. Are they making decisions that position the company for long-term success rather than short-term wins? Are they preserving option value, keeping multiple paths forward rather than betting everything on a single outcome? The best longevity founders play long games extremely well.

Our investment philosophy reflects the unique demands of the longevity sector. We know that raising capital at fair valuations is difficult when timelines are long and outcomes are uncertain. We participate in follow-on rounds, providing the staying power needed to navigate development stages. We connect portfolio companies to strategic partners, advisors, and resources that accelerate progress. And we're direct about the challenges—regulatory hurdles, capital intensity, and high failure rates in drug development.

Transparency about these challenges helps founders prepare. The ones who succeed in longevity are those who enter with eyes wide open, understanding both the opportunities and the obstacles.

The future belongs to biotech and longevity founders. We believed this when we started LongeVC, and the past years have only reinforced it. But not all founders are built for the longevity marathon. Those who succeed combine scientific depth with strategic patience, translational thinking with team-building prowess, and bold vision with financial discipline.

These are the founders changing the trajectory of human healthspan. They’re leveraging biology—from diagnostics to therapies—to help people live healthier and longer lives, not chasing shortcuts or unvalidated claims. They're validating interventions targeting age-related diseases, developing novel diagnostics for early disease detection, and building the infrastructure for personalized longevity medicine. They're the reason we remain committed to investing in longevity, despite the lengthy timelines and high risk.

Because when the right founder with the right team tackles the right problem with the right approach, an ageless future is the question of when, not if.

Are you building a longevity startup? Contact us here to discuss your work.

LongeVC is an international venture capital firm, based in Washington, D.C., investing in visionary biotech and longevity companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthroughs that will change lives and transform the nature of our health. LongeVC is proud to work with its highly involved and expert advisors, investors, and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC and our portfolio companies at www.longevc.com.